<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00924742</url>
  </required_header>
  <id_info>
    <org_study_id>MCPEM08026M1</org_study_id>
    <secondary_id>097-05-160</secondary_id>
    <secondary_id>C163</secondary_id>
    <nct_id>NCT00924742</nct_id>
  </id_info>
  <brief_title>A Single-Dose Pharmacokinetics Study of Tapimycin Injection</brief_title>
  <official_title>A Single-Dose Pharmacokinetics Study of Tapimycin Injection(Piperacillin 4 g + Tazobactam 0.5 g Powder for Injection) Administered Under Fasting Conditions to Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tri-Service General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the pharmacokinetic properties of Tapimycin injection&#xD;
      (piperacillin 4 g + tazobactam 0.5 g powder for injection) in healthy volunteers under&#xD;
      fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To examine the pharmacokinetic properties</measure>
    <time_frame>8.5 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tapimycin (piperacillin 4 g + tazobactam 0.5g)</intervention_name>
    <description>One intravenous infusion (piperacillin 4 g + tazobactam 0.5 g powder for injection) over 30 minutes/single dosing</description>
    <arm_group_label>Test drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed written informed consent before enrollment into the study, ability&#xD;
             to communicate with the investigators, and to understand and comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
          2. Healthy adult male, aged between 20 and 40 years old.&#xD;
&#xD;
          3. Body Mass Index (BMI) between 18.5 and 25.&#xD;
&#xD;
          4. Physically and mentally healthy subjects as confirmed by an interview, medical&#xD;
             history, clinical examination, chest x-ray and electrocardiogram.&#xD;
&#xD;
          5. No significant deviation from normal biochemistry.&#xD;
&#xD;
          6. No significant deviation from normal hematology.&#xD;
&#xD;
          7. No significant deviation from normal urinalysis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of drug or alcohol abuse within the past year.&#xD;
&#xD;
          2. Medical history of severe drug allergy or sensitivity to analogous drug.&#xD;
&#xD;
          3. Acute or chronic diseases or having undergone surgery from 4 weeks prior to PeriodI&#xD;
             dosing.&#xD;
&#xD;
          4. Any clinical significant renal, cardiovascular, hepatic, hematopoietic, neurological,&#xD;
             pulmonary or gastrointestinal pathology.&#xD;
&#xD;
          5. Ongoing peptic ulcer and constipation.&#xD;
&#xD;
          6. Planned vaccination during the time course of the study.&#xD;
&#xD;
          7. Taking any clinical study drug from 3 months prior to Period I dosing.&#xD;
&#xD;
          8. Use of any medication, including herb medicine or vitamins from 4 weeks before the&#xD;
             study.&#xD;
&#xD;
          9. Blood donation of more than 500 mL within the past 3 months.&#xD;
&#xD;
         10. A positive Hepatitis B surface antigen or positive Hepatitis C antibody.&#xD;
&#xD;
         11. A positive test for HIV antibody.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng-Yee Chang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tri-Service General Hospital</affiliation>
  </overall_official>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>June 18, 2009</study_first_submitted>
  <study_first_submitted_qc>June 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2009</study_first_posted>
  <last_update_submitted>June 18, 2009</last_update_submitted>
  <last_update_submitted_qc>June 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Feng-Yee Chang/The Head of Department of Internal Medicine</name_title>
    <organization>Tri-Service General Hospital</organization>
  </responsible_party>
  <keyword>The PK of Tapimycin</keyword>
  <keyword>volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

